Latest Pharma Insights
Nine Companies Trade Lower Prices For No Tariffs In Trump’s MFN Drug Pricing Deals
Amgen, BMS, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck & Co., Novartis and Sanofi will reduce prices of some drugs for Medicaid and offer reduced pricing through direct-to-patient platforms, among other concessions. In exchange, they will be exempted from tariffs.
Scrip - December 20, 2025
Amgen, BMS, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck & Co., Novartis and Sanofi will reduce prices of some drugs for Medicaid and offer reduced pricing through direct-to-patient platforms, among other concessions. In exchange, they will be exempted from tariffs.
Scrip - December 20, 2025
Nine Companies Trade Lower Prices For No Tariffs In Trump’s MFN Drug Pricing Deals
Amgen, BMS, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck & Co., Novartis and Sanofi will reduce prices of some drugs for Medicaid and offer reduced pricing through direct-to-patient platforms, among other concessions. In exchange, they will be exempted from tariffs.
Scrip - December 20, 2025
Amgen, BMS, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck & Co., Novartis and Sanofi will reduce prices of some drugs for Medicaid and offer reduced pricing through direct-to-patient platforms, among other concessions. In exchange, they will be exempted from tariffs.
Scrip - December 20, 2025
HHS Targets Chest Binder Vendors in New Regulatory Crackdown
While the US Department of Health and Human Services presented its Dec. 18 actions limiting access to gender-affirming care as necessary to protect children, a dozen warning letters issued to manufacturers and vendors of chest binders focus on lack of regulatory clearance, rather than consumer age.
Medtech Insight - December 19, 2025
While the US Department of Health and Human Services presented its Dec. 18 actions limiting access to gender-affirming care as necessary to protect children, a dozen warning letters issued to manufacturers and vendors of chest binders focus on lack of regulatory clearance, rather than consumer age.
Medtech Insight - December 19, 2025
Finally A Happy New Year In Switzerland?
As 2025 turns to 2026, Swiss medtechs are anxiously looking to the future on three major fronts, according to Daniel Delfosse, head of regulation and innovation at the national industry association, Swiss Medtech.
Medtech Insight - December 19, 2025
As 2025 turns to 2026, Swiss medtechs are anxiously looking to the future on three major fronts, according to Daniel Delfosse, head of regulation and innovation at the national industry association, Swiss Medtech.
Medtech Insight - December 19, 2025
How EU’s Proposed Regulatory Changes Could Ease Pressures And Drive Growth In Medtech
MedTech Europe’s Petra Zoellner discusses industry's response to EU regulatory proposals aimed at improving notified body operations, transparency, and cost predictability, ultimately fostering innovation in medical technology.
Medtech Insight - December 19, 2025
MedTech Europe’s Petra Zoellner discusses industry's response to EU regulatory proposals aimed at improving notified body operations, transparency, and cost predictability, ultimately fostering innovation in medical technology.
Medtech Insight - December 19, 2025
Philips To Acquire SpectraWAVE To Expand Intravascular Imaging Portfolio
Philips says it intends to fold SpectraWAVE’s intravascular imaging and physiological assessment technologies into its existing intravascular ultrasound ecosystem, including Eagle Eye Platinum catheters and the IntraSight imaging and physiology workspace.
Medtech Insight - December 19, 2025
Philips says it intends to fold SpectraWAVE’s intravascular imaging and physiological assessment technologies into its existing intravascular ultrasound ecosystem, including Eagle Eye Platinum catheters and the IntraSight imaging and physiology workspace.
Medtech Insight - December 19, 2025
Neuroethicists Advocate For More Guidelines For Neurotech
In this second of a three-part series, Medtech Insight spoke with three neuroethicists who raised concerns about privacy, patient safeguards and the need for comprehensive guidelines. These issues are becoming more pressing as BCI companies get ready to commercialize their products.
Medtech Insight - December 19, 2025
In this second of a three-part series, Medtech Insight spoke with three neuroethicists who raised concerns about privacy, patient safeguards and the need for comprehensive guidelines. These issues are becoming more pressing as BCI companies get ready to commercialize their products.
Medtech Insight - December 19, 2025
Futura Sets Sights On Taking Eroxon To China
With the grant of a patent, Futura is hoping to take its Eroxon product to China, a country with a large population of ED sufferers, the firm claims.
HBW Insight - December 19, 2025
With the grant of a patent, Futura is hoping to take its Eroxon product to China, a country with a large population of ED sufferers, the firm claims.
HBW Insight - December 19, 2025
Can US FDA Balance Inspection Generalists And ‘Simple Reform’ With Need For Expertise?
Former agency officials now representing industry worry that a deregulatory bent could be driving "Simple Reform" plan to merge all medical product and clinical research inspectorates and that specialist expertise gained in 2017 "Program Alignment" initiative will be reversed.
HBW Insight - December 19, 2025
Former agency officials now representing industry worry that a deregulatory bent could be driving "Simple Reform" plan to merge all medical product and clinical research inspectorates and that specialist expertise gained in 2017 "Program Alignment" initiative will be reversed.
HBW Insight - December 19, 2025
Lupin Joines Forces With PolyPeptide For Peptide APIs
Lupin has agreed a “long-term strategic alliance” with CDMO PolyPeptide that the firm says will bolster its supply chain for peptide APIs.
Generics Bulletin - December 19, 2025
Lupin has agreed a “long-term strategic alliance” with CDMO PolyPeptide that the firm says will bolster its supply chain for peptide APIs.
Generics Bulletin - December 19, 2025
UK Bodies Warn Market ‘Not Sustainable’ As Prices Hit ‘Rock Bottom’
The UK generics market risks becoming unsustainable as prices hit “rock bottom,” the House of Lords has been warned in a letter signed by multiple stakeholder associations including Medicines UK.
Generics Bulletin - December 19, 2025
The UK generics market risks becoming unsustainable as prices hit “rock bottom,” the House of Lords has been warned in a letter signed by multiple stakeholder associations including Medicines UK.
Generics Bulletin - December 19, 2025
2025 Is A Year Of Firsts As Biosimilars Build Momentum In US
In a busy year for US biosimilars, more than a dozen approvals were seen as multiple brands faced competition for the first time – including Stelara. However, concerns persist over the “biosimilar void”, with hope that the latest FDA announcement on regulatory streamlining can help to fill the gap.
Generics Bulletin - December 19, 2025
In a busy year for US biosimilars, more than a dozen approvals were seen as multiple brands faced competition for the first time – including Stelara. However, concerns persist over the “biosimilar void”, with hope that the latest FDA announcement on regulatory streamlining can help to fill the gap.
Generics Bulletin - December 19, 2025
Alvotech And Teva Are Latest With US Eylea Settlement
Alvotech and Teva have become the latest Eylea biosimilar developers to announce a settlement allowing a US launch in late 2026. However, first they must clear the hurdle of FDA approval following a recent CRL.
Generics Bulletin - December 19, 2025
Alvotech and Teva have become the latest Eylea biosimilar developers to announce a settlement allowing a US launch in late 2026. However, first they must clear the hurdle of FDA approval following a recent CRL.
Generics Bulletin - December 19, 2025
Deals Shaping The Industry, November 2025
An interactive look at pharma, medtech and diagnostics deals made during November 2025. Data courtesy of Biomedtracker.
In Vivo - December 18, 2025
An interactive look at pharma, medtech and diagnostics deals made during November 2025. Data courtesy of Biomedtracker.
In Vivo - December 18, 2025
Aphaia Pushes A Patient-First Vision For Obesity Care
The obesity field is entering the “sobering” phase of the hype cycle; GLP-1 drugs have opened the door but have limitations. Aphaia CSO Steffen-Sebastian Bolz talks to In Vivo about shifting the focus back to patient experience, not just maximal weight loss.
In Vivo - December 18, 2025
The obesity field is entering the “sobering” phase of the hype cycle; GLP-1 drugs have opened the door but have limitations. Aphaia CSO Steffen-Sebastian Bolz talks to In Vivo about shifting the focus back to patient experience, not just maximal weight loss.
In Vivo - December 18, 2025
Inductive Bio, Amgen Join ARPA-H’s Push To Replace Animal Tox With AI And Human Tissues
Inductive Bio receives $21m from ARPA-H to develop AI toxicity models using human tissues, partnering with Amgen to replace animal testing in drug development.
In Vivo - December 18, 2025
Inductive Bio receives $21m from ARPA-H to develop AI toxicity models using human tissues, partnering with Amgen to replace animal testing in drug development.
In Vivo - December 18, 2025
Health Systems Brace For CAR-T ‘Tsunami’
Industry warns healthcare infrastructure – not manufacturing – may be the real bottleneck as cell therapies eye mass-market diseases.
In Vivo - December 18, 2025
Industry warns healthcare infrastructure – not manufacturing – may be the real bottleneck as cell therapies eye mass-market diseases.
In Vivo - December 18, 2025